Research Papers:

Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors

Darren S. Sigal _, Munveer S. Bhangoo, Jonathan A. Hermel, Dean C. Pavlick, Garrett Frampton, Vincent A. Miller, Jeffrey S. Ross and Siraj M. Ali

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:35809-35812. https://doi.org/10.18632/oncotarget.26260

Metrics: PDF 1654 views  |   HTML 2290 views  |   ?  


Darren S. Sigal1, Munveer S. Bhangoo1, Jonathan A. Hermel2, Dean C. Pavlick3, Garrett Frampton3, Vincent A. Miller3, Jeffrey S. Ross3 and Siraj M. Ali3

1Division of Hematology/Oncology, Scripps Clinic Medical Group, La Jolla, CA, USA

2Department of Graduate Medical Education, Tulane University School of Medicine, New Orleans, LA, USA

3Foundation Medicine, Inc. Cambridge, MA, USA

Correspondence to:

Darren S. Sigal, email: [email protected]

Keywords: next-generation sequencing; neuroendocrine tumor; NET; NTRK; neuroendocrine cancer

Received: August 10, 2018     Accepted: October 06, 2018     Published: November 09, 2018


CGP results from >60,000 cases were screened to identify NTRK fusion events from cases of neuroendocrine tumors. 2417 NET patients from diverse anatomic sites were identified. From this dataset, six cases harbored NTRK fusions which included intra- and inter-chromosomal translocations. A NTRK fusion frequency of approximately 0.3% was found across all subtypes of NETs. Three cases involved translocations of NTRK1 with unique fusion partners (GPATCH4, PIP5K1A, CCDC19). Co-occurring alterations occurred in five cases. NTRK alterations were identified in nearly the full spectrum of NETs, including from the small intestine, pancreas, lung, and others. With the late stage clinical development of NTRK TKIs (including entrectinib and larotrectinib), these findings may further inform targeted approaches to therapy in NET.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26260